Von Lubitz D K, Paul I A, Carter M, Jacobson K A
Laboratory of Bioorganic Chemistry, NIH/NIDDK, Bethesda, MD 20892.
Eur J Pharmacol. 1993 Nov 16;249(3):265-70. doi: 10.1016/0014-2999(93)90521-i.
The effect of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) and antagonist 8-cyclopentyl-1,3-dipropylxanthine (CPX) on N-methyl-D-aspartate (NMDA)-evoked seizures was studied in C57BL/6 mice (20/group). Animals were injected i.p. either with CPA (0.5, 1, 2 mg/kg) or CPX (1, 2 mg/kg) 15 min prior to administration of NMDA (30, 60, 125 mg/kg). Administration of NMDA alone resulted in a complete locomotor arrest at 30 mg/kg, while clonic/tonic seizures and progressively increasing mortality were seen at higher doses. Prior administration of CPA resulted either in a delay of seizure onset and unchanged mortality (0.5 mg/kg CPA, 60 mg/kg NMDA) or in elimination of tonic episodes and a significant reduction in postictal mortality (1, 2 mg/kg CPA; 60, 125 mg/kg NMDA). Pretreatment with CPX at either 1 or 2 mg/kg eliminated locomotor depression in animals injected with NMDA at 30 mg/kg. At 60 mg/kg NMDA, the effect of CPX administration resulted in mortality equivalent to that seen with 125 mg/kg NMDA administered alone. The results indicate that A1 receptor agonists may protect against NMDA-evoked seizures and that the adenosine A1 receptor may be directly involved in these actions.
在C57BL/6小鼠(每组20只)中研究了腺苷A1受体激动剂N6-环戊基腺苷(CPA)和拮抗剂8-环戊基-1,3-二丙基黄嘌呤(CPX)对N-甲基-D-天冬氨酸(NMDA)诱发癫痫发作的影响。在给予NMDA(30、60、125mg/kg)前15分钟,给动物腹腔注射CPA(0.5、1、2mg/kg)或CPX(1、2mg/kg)。单独给予NMDA时,30mg/kg会导致完全运动停滞,而在更高剂量时会出现阵挛/强直发作以及死亡率逐渐增加。预先给予CPA要么会延迟癫痫发作起始且死亡率不变(0.5mg/kg CPA,60mg/kg NMDA),要么会消除强直发作阶段并显著降低发作后死亡率(1、2mg/kg CPA;60、125mg/kg NMDA)。用1或2mg/kg的CPX预处理可消除注射30mg/kg NMDA动物的运动抑制。在60mg/kg NMDA时,给予CPX的效果导致的死亡率与单独给予125mg/kg NMDA时相当。结果表明,A1受体激动剂可能对NMDA诱发的癫痫发作具有保护作用,并且腺苷A1受体可能直接参与这些作用。